Table 1. Performance of single test strategies to predict CIN2+ and CIN3+ histology among HIV positive and HIV negative cohorts (with 95% CI)

HIV-positive women, HPW (n=456)		Histology diagnosis used to calculate test performance									
Test (threshold)	Positivity rate % [95% CI]	CIN2+ histology CIN2+ Prevalence: 203/456 (44.5%)				CIN3+ histology CIN3+ Prevalence: 106/456 (23.3%); ICC prevalence: 13/456 (2.9%)					
Performance indicators	Referral to treatment	Sensitivity % [95% CI]	Specificity % [95% CI]	PPV % [95% CI]	NPV % [95% CI]	Sensitivity % [95% CI]	Specificity % [95% CI]	PPV % [95% CI]	NPV % [95% CI]		
A: Visual inspection (VIA?)	47.8	66.5	67.2	61.9	71.4	75.5	60.6	36.7	89.1		
	[43.2-52.4]	[60.0-73.0]	[61.4-73.0]	[55.4-68.4]	[65.7-77.2]	[67.2-86.8]	[55.4-65.7]	[30.3-43.1]	[85.1-93.0]		
B: Visual inspection	50.4	67.0	62.9	59.1	70.4	76.4	57.4	35.2	88.9		
(VILI?)	[45.8-55.0]	[60.5-73.5]	[56.9-68.8]	[52.7-65.5]	[64.4-76.3]	[68.3-84.6]	[52.2-62.6]	[29.0-41.4]	[84.8-93.1]		
C: Cytology(ASCUS)	39.9	63.6	79.1	70.9	73.0	75.5	70.9	44.0	90.5		
	[35.4-44.1]	[56.9-70.2]	[74.0-84.1]	[64.2-77.5]	[66.5-79.5]	[67.2-83.8]	[66.1-75.6]	[36.7-51.2]	[87.0-94.0]		
D: Cytology(LSIL)	33.4	55.7	90.5	83.0	71.1	71.2	82.0	54.8	90.3		
	[29.0-37.8]	[48.8-62.6]	[86.8-94.2]	[76.6-89.4]	[63.4-78.8]	[62.3-80.0]	[77.9-86.1]	[46.3-63.3]	[86.9-93.6]		
E: hrHPV(any)	48.5	78.8	75.9	72.4	81.7	82.1	61.7	39.4	91.9		
	[43.9-53.1]	[73.2-84.5]	[70.6-81.2]	[66.5-78.3]	[76.6-86.8]	[74.7-89.5]	[56.6-66.8]	[32.9-45.8]	[88.4-95.4]		
HIV-negative women, HNW (n=648)		Histology diagnosis used to calculate test performance									
Test (threshold)	Positivity rate % [95% CI]	CIN2+ prevalence: 164/648 (25.3%)				CIN3+ prevalence: 67/648 (10.3%); ICC prevalence: 9/648 (1.4%)					
Performance indicators	Referral to treatment	Sensitivity % [95% CI]	Specificity % [95% CI]	PPV % [95% CI]	NPV % [95% CI]	Sensitivity % [95% CI]	Specificity % [95% CI]	PPV % [95% CI]	NPV % [95% CI]		
A: Visual inspection (VIA?)	18.7	35.6	87.0	47.9	80.0	50.0	84.9	27.3	93.7		
	[15.7-21.7]	[28.2-43.0]	[84.0-90.0]	[38.9-56.9]	[76.6-83.5]	[37.7-62.3]	[81.9-87.8]	[19.3-35.3]	[91.7-95.8]		
B: Visual inspection	20.9	35.6	84.1	43.0	79.5	51.5	82.6	25.2	93.8		
(VILI?)	[17.7-24.0]	[28.2-43.0]	[80.8-87.4]	[34.5-51.4]	[72.6-86.4]	[39.2-63.8]	[79.5-85.7]	[17.8-32.6]	[91.7-95.9]		
C: Cytology(ASCUS)	17.0	41.7	91.3	61.8	82.3	59.1	87.8	35.5	95.0		
	[14.1-20.0]	[34.1-49.3]	[88.8-93.9]	[52.6-71.0]	[75.1-89.6]	[47.0-71.2]	[85.1-90.5]	[26.4-44.5]	[93.1-96.8]		
D: Cytology(LSIL)	8.0	20.1	97.5	72.7	78.7	35.9	96.4	52.3	93.1		
	[5.9-10.1]	[13.9-26.4]	[96.1-98.9]	[59.2-86.3]	[66.3-91.2]	[24.0-47.9]	[94.8-97.9]	[37.1-67.5]	[91.1-95.2]		
E: hrHPV(any)	23.5	49.1	85.2	52.6	83.3	68.2	81.6	29.6	95.8		
	[20.2-26.7]	[41.4-56.8]	[82.0-88.3]	[44.6-60.6]	[77.3-89.3]	[56.7-79.3]	[78.5-84.8]	[22.3-36.9]	[94.0-97.5]		

CIN2+ = cervical squamous intraepithelial neoplasia grade 2 or worse; CIN3+ = cervical squamous intraepithelial neoplasia grade 3 or worse; ICC = invasive cervical cancer; VIA? = visual inspection with acetic acid uncertain or worse; VILI? = visual inspection with Lugol's iodine uncertain or worse; ASCUS+ = atypical squamous cells of unknown significance or worse result; LSIL+ = low grade squamous intra-epithelial lesion or worse result; any = any of the 14 specified high risk HPV DNA types; 95% CI = 95% Confidence interval

Table 2: Performance of combination test strategies using a dual result approach (high- and low-risk result) among HIV-positive and HIV-negative cohorts (with 95% CI).

HIV-positive women, HPW (n=456)	Test positivity rate	Histology diagnosis used to calculate test performance							
Test 1 (threshold); Test 2 (threshold)	Primary test positive: Test 1 as primary	Primary test positive: Test 2 as primary	Dual test positive: High-risk group	CIN3+ prevalence: 1		CIN2+ prevalence: 203/456 (44.5%)			
Performance indicators	Reflex to second test %	Reflex to second test %	Refer to treatment %	Sensitivity %	NPV %	Specificity %	PPV %		
	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]		
F: Visual inspection (VIA?);	47.8	39.9	28.3	64.2	88.4	90.9	82.2		
Cytology (ASCUS+)	[43.2-52.4]	[35.4-44.1]	[24.1-32.4]	[54.9-73.4]	[84.9-91.9]	[87.4-94.5]	[75.5-88.8]		
G: Visual inspection (VIA?);	47.8	33.4	25.0	62.3	88.3	93.7	86.0		
Cytology (LSIL+)	[43.2-52.4]	[29.0-37.8]	[21.0-29.0]	[52.9-71.6]	[84.9-91.7]	[90.7-96.7]	[79.5-92.4]		
H: Visual inspection (VIA?);	47.8	48.5	29.8	67.0	89.1	91.7	84.6		
hrHPV (any)	[43.2-52.4]	[43.9-53.1]	[25.6-34.0]	[57.9-76.0]	[85.6-92.5]	[88.3-95.1]	[78.4-9.7]		
I: hrHPV (any);	48.5	39.9	31.4	70.8	90.1	90.9	83.9		
Cytology (ASCUS+)	[43.9-53.1]	[35.4-44.1]	[27.1-35.6]	[62.0-79.5]	[86.8-93.4]	[87.4-94.5]	[77.8-90.0]		
J: hrHPV (any);	48.5	33.4	28.1	68.9	90.0	92.5	85.2		
Cytology (LSIL+)	[43.9-53.1]	[29.0-37.8]	[23.9-32.2]	[60.0-77.8]	[86.7-93.2]	[89.2-95.8]	[78.9-91.4]		
K: hrHPV (any);	48.5	N/A	17.1	37.7	82.5	96.4	88.5		
HPV (16/18)	[43.9-53.1]	N/A	[13.6-20.6]	[28.4-47.1]	[78.7-86.4]	[94.2-98.4]	[81.3-95.7]		
L: hrHPV (any); HPV16/18 OR Cytology	48.5	N/A	34.7	73.6	90.6	89.7	83.5		
(ASCUS+) *	[43.9-53.1]	N/A	[30.3-39.0]	[65.1-82.1]	[87.3-93.9]	[86.0-93.5]	[77.7-89.4]		
HIV-negative women, HPW	T4			Historia and dia ana a sia					
(n=648)	Test positivity rate			Histology diagnosis used to calculate test performance					
Test 1 (threshold);	Primary test positive:	Primary test positive: Dual test positive:		CIN3+ prevalence: 6	67/648 (10.3%);	CIN2+ prevalence: 164/648 (25.3%)			
Test 2 (threshold)	Test 1 as primary Test 2 as primary		High-risk group	ICC prevalence: 9/6	48 (1.4%)				
Performance indicators	Reflex to second test %	Reflex to second test %	Refer to treatment %	Sensitivity %	NPV %	Specificity %	PPV %		
	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]		
F: Visual inspection (VIA?);	18.7	17.0	8.2	42.4	93.6	96.9	71.7		
Cytology (ASCUS+)	[15.7-21.7]	[14.1-20.0]	[6.1-10.3]	[30.3-54.8]	[91.6-95.6]	[95.4-98.5]	[59.3-84.1]		
G: Visual inspection (VIA?);	18.7	8.0	5.3	30.3	92.5	98.6	79.4		
Cytology (LSIL+)	[15.7-21.7]	[5.9-10.1]	[3.5-7.0]	[19.0-41.6]	[90.4-54.6]	[97.5-99.6]	[65.3-93.5]		
H: Visual inspection (VIA?);	18.7	23.5	7.4	43.9	93.8	97.7	77.1		
						**	[640.00.0]		
hrHPV (any)	[15.7-21.7]	[20.2-26.7]	[5.4-9.4]	[31.7-56.1]	[91.9-95.8]	[96.4-99.1]	[64.9-89.3]		
hrHPV (any) I: hrHPV (any);	[15.7-21.7] 23.5	[20.2-26.7] 17.0	[5.4-9.4] 10.2	[31.7-56.1] 50.0	[91.9-95.8] 94.3	[96.4-99.1] 96.5	[64.9-89.3] 74.2		
				· · · · · · · · · · · · · · · · · · ·					
I: hrHPV (any);	23.5	17.0	10.2	50.0	94.3	96.5	74.2		
I: hrHPV (any); Cytology (ASCUS+)	23.5 [20.2-26.7]	17.0 [14.1-20.0]	10.2 [7.9-12.5]	50.0 [37.7-62.3]	94.3 [92.5-96.2]	96.5 [94.9-98.1]	74.2 [63.5-85.0]		
I: hrHPV (any); Cytology (ASCUS+) J: hrHPV (any);	23.5 [20.2-26.7] 23.5	17.0 [14.1-20.0] 8.0 [5.9-10.1]	10.2 [7.9-12.5] 5.7	50.0 [37.7-62.3] 33.3	94.3 [92.5-96.2] 92.8	96.5 [94.9-98.1] 98.4	74.2 [63.5-85.0] 78.4		
I: hrHPV (any); Cytology (ASCUS+) J: hrHPV (any); Cytology (LSIL+)	23.5 [20.2-26.7] 23.5 [20.2-26.7]	17.0 [14.1-20.0] 8.0	10.2 [7.9-12.5] 5.7 [3.9-7.5]	50.0 [37.7-62.3] 33.3 [21.7-44.9]	94.3 [92.5-96.2] 92.8 [90.7-94.9]	96.5 [94.9-98.1] 98.4 [97.2-99.5]	74.2 [63.5-85.0] 78.4 [64.7-92.1]		
I: hrHPV (any); Cytology (ASCUS+) J: hrHPV (any); Cytology (LSIL+) K: hrHPV (any);	23.5 [20.2-26.7] 23.5 [20.2-26.7] 23.5	17.0 [14.1-20.0] 8.0 [5.9-10.1]	10.2 [7.9-12.5] 5.7 [3.9-7.5] 7.6	50.0 [37.7-62.3] 33.3 [21.7-44.9] 34.9	94.3 [92.5-96.2] 92.8 [90.7-94.9] 92.8	96.5 [94.9-98.1] 98.4 [97.2-99.5] 96.7	74.2 [63.5-85.0] 78.4 [64.7-92.1] 67.4		

CIN2+ = cervical squamous intraepithelial neoplasia grade 2 or worse; CIN3+ = cervical squamous intraepithelial neoplasia grade 3 or worse; ICC = invasive cervical cancer; VIA? = visual inspection with acetic acid with result of uncertain or worse; ASCUS+ = atypical squamous cells of unknown significance or worse result; LSIL+ = low grade squamous intraepithelial lesion or worse result; any = any of the 14 specified high risk HPV DNA types; 16/18 = positive for HPV DNA of either HPV16 or HPV18 or both 95% CI = 95% Confidence interval

^{*}Test 2 is defined as the combination of partial genotyping (HPV16/18) and cytology (threshold ASCUS) for hrHPV positives who are not HPV16/18 positive.

Table 3: Performance of combination test strategies using a triple result approach (high-, intermediate- and low-risk results) among HIV-positive and HIV-negative cohorts (with 95% CI)

Screening sequence 1:			Screening sequence 2:			Performance of strategy			
Test 1 as primary and Test 2 as secondary test			Test 2 as primary and Test	st 1 as secondary test					
Single test positive: Intermediate-risk group	CIN3+ prevalence: 106/456 (23.3%); ICC prevalence: 13/456 (2.9%)		Single test positive: Intermediate-risk group	CIN3+ prevalence: 106/456 (23.3%); ICC prevalence: 13/456 (2.9%)		Dual test positive: High-risk group	CIN2+ prevalence: 203/456 (44.5%)		
Recall for follow-up	Sensitivity	NPV	Recall for	Sensitivity	NPV	Refer to treatment	Specificity	PPV	
%	%	%	follow-up %	%	%	%	%	%	
[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	
19.5	75.5	89.1	11.6	75.5	90.5	28.3	90.9	82.2	
[15.7 to 24.0]		[85.1-93.0]	[8.7-15.2]	[67.2-83.8]	[87.0-94.0	[24.1-32.4]	[87.4-94.5]	[75.5-88.8]	
22.8	75.5	89.1	7.5	71.2	90.3	25.0	93.7	86.0	
[18.6-27.6]	[67.2-86.8]	[85.1-93.0]	[5.2-10.4]	[62.3-80.0]	[86.9-93.6]	[21.0-30.0]	[90.7-96.7]	[79.5-92.4]	
18.0	75.5	89.1	18.6	82.1	91.9	29.8	91.7	84.6	
[14.3-22.3]	[67.2-86.8]	[85.1-93.0]	[14.9-23.1]	[74.7-89.5]	[88.4-95.4]	[25.6-34.0]	[88.3-95.1]	[78.4-9.7]	
17.1	82.1	91.9	8.6	75.5	90.5	31.4	90.9	83.9	
[13.5-21.4]	[74.7-89.5]	[88.4-95.4]	[6.1-11.7]	[67.2-83.8]	[87.0-94.0	[27.1-35.6]	[87.4-94.5]	[77.8-90.0]	
20.4	82.1	91.9	4.4	71.2	90.3	28.1	92.5	85.2	
[16.5-25.0]	[74.7-89.5]	[88.4-95.4]	[2.7-6.8]	[62.3-80.0]	[86.9-93.6]	[23.9-32.2]	[89.2-95.8]	[78.9-91.4]	
31.4	82.1	91.9	NI/A	NI/A	NI/A	17.1	96.4	88.5	
[26.4-36.9]	[74.7-89.5]	[88.4-95.4]	N/A	N/A	N/A	[13.6-20.6]	[94.2-98.4]	[81.3-95.7]	
13.8	82.1	91.9	N1/A	NI/A	N1/A	34.7	89.7	83.5	
[10.6-17.7]	[74.7-89.5]	[88.4-95.4]	IN/A	N/A	N/A	[30.3-39.0]	[86.0-93.5]	[77.7-89.4]	
Screening sequence 1:			Screening sequence 2:			Performance of strategy			
Test 1 as primary and Test 2	as secondary test		Test 2 as primary and Test	st 1 as secondary test					
Single test positive:	CIN3+ prevalence:	67/648 (10.3%);	Single test positive: CIN3+ prevalence: 67/648 (10.3%);		Dual test positive: CIN2+ prevalence:				
Intermediate-risk group ICC prevalence: 9/648 (1.4%)			Intermediate-risk	ICC prevalence: 9/648 (1.4%)		High-risk group 164/648 (25.3%)			
			group						
•			•	Sensitivity		Refer to treatment	Specificity	PPV	
%	%	%	0/						
			%	%	%	%	%	%	
[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	[95% CI]	
10.7	50.0	[95% CI] 93.7	[95% CI] 8.8	[95% CI] 59.1	[95% CI] 95.0	[95% CI] 8.2	[95% CI] 96.9	[95% CI] 71.7	
10.7 [8.3-13.5]	50.0 [37.7-62.3]	[95% CI] 93.7 [91.7-95.8]	[95% CI] 8.8 [6.7-11.4]	[95% CI] 59.1 [47.0-71.2]	[95% CI] 95.0 [93.1-96.8]	[95% CI] 8.2 [6.1-10.3]	[95% CI] 96.9 [95.4-98.5]	[95% CI] 71.7 [59.3-84.1]	
10.7 [8.3-13.5] 13.5	50.0 [37.7-62.3] 50.0	[95% CI] 93.7 [91.7-95.8] 93.7	[95% CI] 8.8 [6.7-11.4] 2.8	[95% CI] 59.1 [47.0-71.2] 35.9	[95% CI] 95.0	[95% CI] 8.2 [6.1-10.3] 5.3	[95% CI] 96.9 [95.4-98.5] 98.6	[95% CI] 71.7 [59.3-84.1] 79.4	
10.7 [8.3-13.5] 13.5 [10.9-16.7]	50.0 [37.7-62.3] 50.0 [37.7-62.3]	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5]	
10.7 [8.3-13.5] 13.5	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0	[95% CI] 93.7 [91.7-95.8] 93.7	[95% CI] 8.8 [6.7-11.4] 2.8	[95% CI] 59.1 [47.0-71.2] 35.9	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8	[95% CI] 8.2 [6.1-10.3] 5.3	[95% CI] 96.9 [95.4-98.5] 98.6	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2]	50.0 [37.7-62.3] 50.0 [37.7-62.3]	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5]	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4]	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3]	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3]	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4] 17.8	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3] 68.2	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1] 2.2	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3] 59.1	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1] 96.5	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4] 17.8 [14.7-21.3]	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3] 68.2 [56.7-79.3] 68.2 [56.7-79.3]	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8 [94.0-97.5] 95.8 [94.0-97.5]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3] 59.1 [47.0-71.2]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5] 95.0 [93.1-96.8]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4] 10.2 [7.9-12.5] 5.7 [3.9-7.5]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1] 96.5 [94.9-98.1] 98.4 [97.2-99.5]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2 [63.5-85.0] 78.4 [64.7-92.1]	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4] 17.8 [14.7-21.3]	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3] 68.2 [56.7-79.3] 68.2 [56.7-79.3] 68.2	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8 [94.0-97.5] 95.8 [94.0-97.5]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1] 2.2 [1.2-3.6]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3] 59.1 [47.0-71.2] 35.9 [24.0-47.9]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5] 95.0 [93.1-96.8] 93.1 [91.1-95.2]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4] 10.2 [7.9-12.5] 5.7 [3.9-7.5] 7.6	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1] 96.5 [94.9-98.1] 98.4 [97.2-99.5]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2 [63.5-85.0] 78.4 [64.7-92.1]	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4] 17.8 [14.7-21.3]	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3] 68.2 [56.7-79.3] 68.2 [56.7-79.3]	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8 [94.0-97.5] 95.8 [94.0-97.5]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1] 2.2	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3] 59.1 [47.0-71.2] 35.9	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5] 95.0 [93.1-96.8]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4] 10.2 [7.9-12.5] 5.7 [3.9-7.5] 7.6 [5.5-9.6]	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1] 96.5 [94.9-98.1] 98.4 [97.2-99.5]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2 [63.5-85.0] 78.4 [64.7-92.1] 67.4 [53.9-80.8]	
10.7 [8.3-13.5] 13.5 [10.9-16.7] 11.3 [8.8-14.2] 13.3 [10.6-16.4] 17.8 [14.7-21.3]	50.0 [37.7-62.3] 50.0 [37.7-62.3] 50.0 [37.7-62.3] 68.2 [56.7-79.3] 68.2 [56.7-79.3] 68.2	[95% CI] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 93.7 [91.7-95.8] 95.8 [94.0-97.5] 95.8 [94.0-97.5]	[95% CI] 8.8 [6.7-11.4] 2.8 [1.6-4.4] 16.1 [13.1-19.5] 6.8 [4.9-9.1] 2.2 [1.2-3.6]	[95% CI] 59.1 [47.0-71.2] 35.9 [24.0-47.9] 68.2 [56.7-79.3] 59.1 [47.0-71.2] 35.9 [24.0-47.9]	[95% CI] 95.0 [93.1-96.8] 93.1 [91.1-95.2] 95.8 [94.0-97.5] 95.0 [93.1-96.8] 93.1 [91.1-95.2]	[95% CI] 8.2 [6.1-10.3] 5.3 [3.5-7.0] 7.4 [5.4-9.4] 10.2 [7.9-12.5] 5.7 [3.9-7.5] 7.6	[95% CI] 96.9 [95.4-98.5] 98.6 [97.5-99.6] 97.7 [96.4-99.1] 96.5 [94.9-98.1] 98.4 [97.2-99.5]	[95% CI] 71.7 [59.3-84.1] 79.4 [65.3-93.5] 77.1 [64.9-89.3] 74.2 [63.5-85.0] 78.4 [64.7-92.1]	
	Test 1 as primary and Test 2 Single test positive: Intermediate-risk group Recall for follow-up % [95% CI] 19.5 [15.7 to 24.0] 22.8 [18.6-27.6] 18.0 [14.3-22.3] 17.1 [13.5-21.4] 20.4 [16.5-25.0] 31.4 [26.4-36.9] 13.8 [10.6-17.7] Screening sequence 1: Test 1 as primary and Test 2 Single test positive:	Test 1 as primary and Test 2 as secondary test Single test positive: CIN3+ prevalence: Intermediate-risk group CC prevalence: 13 Recall for follow-up Sensitivity % % [95% CI] [95% CI] 19.5 75.5 [15.7 to 24.0] [67.2-86.8] 22.8 75.5 [18.6-27.6] [67.2-86.8] 18.0 75.5 [14.3-22.3] [67.2-86.8] 17.1 82.1 [13.5-21.4] [74.7-89.5] 31.4 82.1 [26.4-36.9] [74.7-89.5] 31.8 82.1 [10.6-17.7] [74.7-89.5] Screening sequence 1: Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group ICC prevalence: 9/ Recall for follow-up Sensitivity	Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group CIN3+ prevalence: 106/456 (23.3%); ICC prevalence: 13/456 (2.9%) Recall for follow-up % Sensitivity % NPV % % 95 CI] [95% CI] [95% CI] 19.5 75.5 89.1 [15.7 to 24.0] [67.2-86.8] [85.1-93.0] 22.8 75.5 89.1 [18.6-27.6] [67.2-86.8] [85.1-93.0] 18.0 75.5 89.1 [14.3-22.3] [67.2-86.8] [85.1-93.0] 17.1 82.1 91.9 [13.5-21.4] [74.7-89.5] [88.4-95.4] 20.4 82.1 91.9 [16.5-25.0] [74.7-89.5] [88.4-95.4] 31.4 82.1 91.9 [26.4-36.9] [74.7-89.5] [88.4-95.4] Screening sequence 1: 13.8 82.1 91.9 [50.6-17.7] [74.7-89.5] [88.4-95.4] Screening sequence 1: 15.7 15.7 15.7 1 as primary and Test 2 as seconda	Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group ICC prevalence: 106/456 (23.3%); ICC prevalence: 13/456 (2.9%) Intermediate-risk group Sensitivity NPV Recall for follow-up % % % follow-up % [95% CI] [9	Test 1 as primary and Test 2 as secondary test Single test positive: CIN3+ prevalence: 106/456 (23.3%); Single test positive: Intermediate-risk group CIN3+ prevalence: 13/456 (2.9%) Single test positive: Intermediate-risk group CIN3+ prevalence: 13/456 (2.9%) Single test positive: Intermediate-risk group CIN3+ prevalence: 13/456 (2.9%) Single test positive: Intermediate-risk group CIN3+ prevalence: 13/456 (2.9%) CIN3+ prevalence: 14/4	Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group ICC prevalence: 13/456 (2.9%) Single test positive: Intermediate-risk group ICC prevalence: 13/456 (2.9%) ICC prevalence: 10/456 (2.9%) ICC pre	Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group ICC prevalence: 13/456 (2.9%) ICC prevalence: 13/456 (2	Test 1 as primary and Test 2 as secondary test Single test positive: Intermediate-risk group CIN3+ prevalence: 106/456 (23.3%); Intermediate-risk group CIN3+ prevalence: 13/456 (2.9%) ICC prevalence: 13/456 (2.9%) ICC prevalence: 13/456 (2.9%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group Intermediate-risk group CIN3+ prevalence: 203/456 (44.5%) ICC prevalence: 13/456 (2.9%) Intermediate-risk group Intermediate-risk grou	

Intermediate risk group = single test positive, recall for follow-up; High risk group = double test positive, for treatment; Low risk group = double test negative, for routine screening interval; CIN3+ = cervical squamous intraepithelial neoplasia grade 3 or worse; CIN2+ = cervical squamous intraepithelial neoplasia grade 2 or worse; VIA? = visual inspection with acetic acid with result of uncertain or worse; ASCUS+ = atypical squamous cells of unknown significance or worse result; LSIL+ = low grade squamous intra-epithelial lesion or worse result; any = positive for any of the 14 specified high risk HPV DNA types; 16/18 = positive for HPV DNA of either HPV16 or HPV18 or both; 95% CI = 95% Confidence interval